Intercept failed NASH candidate precipitated Alfasigma acquisition Markets September 30, 2023 [ad_1] Mohammed Haneefa Nizamudeen After the failure of Intercept Prescribed drugs’ (ICPT) Ocaliva (obeticolic acid) for nonalcoholic steatohepatitis (NASH) in…
Canaccord cuts Intercept to hold, calls Alfasigma deal “best possible outcome” (ICPT) Markets September 27, 2023 [ad_1] Maksim Labkouski Intercept Prescribed drugs (NASDAQ:ICPT) has been downgraded to carry by Canaccord Genuity within the wake of stories…
